BiondVax Pharmaceuticals Ltd ADR
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $4.13 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
BiondVax Pharmaceuticals Ltd ADR had its IPO on 2015-05-12 under the ticker symbol BVXV.
The company operates in the Healthcare sector and Biotechnology industry. BiondVax Pharmaceuticals Ltd ADR has a staff strength of 15 employees.
Shares of BiondVax Pharmaceuticals Ltd ADR opened at $2.18 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $2.1 - $2.18, and closed at $2.14.
This is a -0.93% slip from the previous day's closing price.
A total volume of 18,663 shares were traded at the close of the day’s session.
In the last one week, shares of BiondVax Pharmaceuticals Ltd ADR have slipped by -1.83%.
BiondVax Pharmaceuticals Ltd ADR's Key Ratios
BiondVax Pharmaceuticals Ltd ADR has a market cap of $4.13 million, indicating a price to book ratio of 7.4836 and a price to sales ratio of 0.
In the last 12-months BiondVax Pharmaceuticals Ltd ADR’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures BiondVax Pharmaceuticals Ltd ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, BiondVax Pharmaceuticals Ltd ADR’s operating margin was 0% while its return on assets stood at -20.98% with a return of equity of -432.25%.
In Q3, BiondVax Pharmaceuticals Ltd ADR’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
BiondVax Pharmaceuticals Ltd ADR’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-4.45 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into BiondVax Pharmaceuticals Ltd ADR’s profitability.
BiondVax Pharmaceuticals Ltd ADR stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.0671. Its price to sales ratio in the trailing 12-months stood at 0.
BiondVax Pharmaceuticals Ltd ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $74.72 million
- Total Liabilities
- $5.24 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
BiondVax Pharmaceuticals Ltd ADR ended 2023 with $74.72 million in total assets and $0 in total liabilities. Its intangible assets were valued at $74.72 million while shareholder equity stood at $9.36 million.
BiondVax Pharmaceuticals Ltd ADR ended 2023 with $0 in deferred long-term liabilities, $5.24 million in other current liabilities, in common stock, $-383292000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $29.44 million and cash and short-term investments were $29.44 million. The company’s total short-term debt was $2,001,000 while long-term debt stood at $55.39 million.
BiondVax Pharmaceuticals Ltd ADR’s total current assets stands at $30.16 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $713000.00 compared to accounts payable of $1.05 million and inventory worth $0.
In 2023, BiondVax Pharmaceuticals Ltd ADR's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, BiondVax Pharmaceuticals Ltd ADR paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
BiondVax Pharmaceuticals Ltd ADR stock is currently trading at $2.14 per share. It touched a 52-week high of $19.65 and a 52-week low of $19.65. Analysts tracking the stock have a 12-month average target price of $57.
Its 50-day moving average was $2.39 and 200-day moving average was $7.43 The short ratio stood at 1.28 indicating a short percent outstanding of 0%.
Around 2774.7% of the company’s stock are held by insiders while 1284.4% are held by institutions.
Frequently Asked Questions About BiondVax Pharmaceuticals Ltd ADR
Similar Industry Stocks (Biotechnology)
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.